Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.
SinoMab BioScience Limited announced the passing of Mr. Dylan Carlo Tinker, an independent non-executive director and a member of both the audit and nomination committees. This unfortunate event has left the company temporarily non-compliant with the Hong Kong Stock Exchange’s listing rules, as the nomination committee no longer has a majority of independent non-executive directors. The company plans to appoint a suitable replacement within three months to rectify this situation. Additionally, due to Mr. Tinker’s passing, the resolution for his re-election will be withdrawn from the upcoming annual general meeting agenda.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, specializing in the research and development of therapeutic products. The company focuses on creating innovative treatments for autoimmune diseases, leveraging its expertise in monoclonal antibody technology.
Average Trading Volume: 3,614,379
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$2.54B
For an in-depth examination of 3681 stock, go to TipRanks’ Stock Analysis page.